Extract from the Clinical Evaluation Report for Talimogene ...

Pregnancy and Lactation: Adequate and well controlled studies with talimogene laherparepvec have not been conducted in pregnant women. If a pregnant woman has a primary infection with wild type HSV-1 or reactivation of a previous wild-type HSV-1 infection, there is potential for the virus to cross the placental barrier, and also a risk of transmission during birth due to viral shedding. ................
................